CAMBRIDGE, Mass., June 11, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage
biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular
diseases, granted an equity award on June 7, 2018 (“Date of Hire”), that was approved by the Compensation Committee of its Board of
Directors, as a material inducement to employment to Dr. Gilmore O’Neill in connection with his appointment as Sarepta’s new Senior
Vice President, Chief Medical Officer. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Dr. O’Neill received an award of 12,000 restricted stock units (“RSUs”) issued under Sarepta’s 2014 Employment
Commencement Incentive Plan. The RSUs shall vest on May 23, 2019.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of
precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the
development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please
visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our
website at www.sarepta.com. We encourage investors and potential investors to consult our
website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
iestepan@sarepta.com
or
W2O Group
Brian Reid, 212-257-6725
breid@w2ogroup.com
